Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Effect of Roflumilast in COPD Patients Treated With Salmeterol. A 24-week, Double-blind Study With 500 μg Roflumilast Once Daily Versus Placebo. The EOS Study

NCT00313209 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT00313209
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00313209 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Effect of Roflumilast in COPD Patients Treated With Salmeterol. A 24-week, Double-blind Study With 500 μg Roflumilast Once Daily Versus Placebo. The EOS Study
Lead sponsor
AstraZeneca
Phase
Phase 3
Overall status
Completed
Start date
April 30, 2006
Completion date
February 29, 2008
Enrollment
933 (actual)
Sites
134

Conditions

As the registry lists them; a condition with its own page is linked.

chronic obstructive pulmonary disease (copd)